BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24769318)

  • 1. Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion.
    Beauverd Y; Roosnek E; Tirefort Y; Nagy-Hulliger M; Bernimoulin M; Tsopra O; Ansari M; Dantin C; Casini A; Grandjean AP; Chigrinova E; Masouridi-Levrat S; Chalandon Y
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1322-8. PubMed ID: 24769318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index.
    Beauverd Y; Roosnek E; Tirefort Y; Dantin C; Ansari M; Tsopra O; Masouridi-Levrat S; Chalandon Y
    Bone Marrow Transplant; 2016 Jul; 51(7):955-60. PubMed ID: 26950373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
    Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan.
    Numata A; Tanaka M; Matsumoto K; Takasaki H; Tachibana T; Fujimaki K; Sakai R; Fujisawa S; Tomita N; Fujita H; Maruta A; Ishigatsubo Y; Kanamori H
    Clin Transplant; 2014 Apr; 28(4):403-9. PubMed ID: 24655161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
    Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hematopoietic reconstitution on the prognosis of hematological malignancies after allogeneic hematopoietic stem cell transplantation].
    Zhang Y; Ren HY; Qiu ZX; Wang MJ; Xu WL; Liu W; Li Y; Dong YJ; Yin Y; Sun YH; Wang LH; Ou JP; Wang WS; Cen XN
    Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):747-50. PubMed ID: 23336230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The influence of liver dysfunction before transplantation and during conditioning period on the outcome of allogeneic hematopoietic stem cell transplantation].
    Zhao J; Ren H; Qiu Z; Wang M; Liu W; Xu W; Li Y; Sun Y; Wang L; Liang Z; Dong Y; Ou J; Wang W; Yin Y; Cen X; Wang Q
    Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):99-103. PubMed ID: 24767159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
    Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
    J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic significance of EBMT score system for hematological malignancies with allogeneic hematopoietic stem cell transplantation].
    Wang L; Tang W; Fan X; Zhao WL; Chen YB; Shen ZX; Li JM; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):655-8. PubMed ID: 23978014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.